Erasmus School of Health Policy & Management
Endowed professor | Health Technology Assessment (HTA)
- retel@eshpm.eur.nl
More information
Work
- Sabine E. Breukers, Joleen J.H. Traets, Stan W. van Dijk, Mercedes Machuca Ostos, Itske Fraterman, Robert D. Crommelin, Hedda van der Hulst, Xiaohang Qiao, Thomas Boere, Lonneke V. van de Poll-Franse, Valesca Retèl, Vincent van der Noort, Joris L. Vos, Alexandra G.L. Toppenberg, Martijn van der Heijden, Francesco Missale, Fons Balm, Michiel van den Brekel, Richard Dirven, M. Baris Karakullukcu, Luc Karssemakers, W. Martin C. Klop, Peter J.F.M. Lohuis, Willem H. Schreuder, Ludi E. Smeele, Lilly Ann van der Velden, Elsemieke Plasmeijer, Laura A. Smit, Jan Paul de Boer, Arash Navran, Bram Westerink, Petra K. de Koekkoek-Doll, Jonas Castelijns, Maurits Wondergem, Wouter V. Vogel, Anke Kuijpers, Winan J. van Houdt, Suzanne Onderwater, Esther Maas-Bannink, Sten Cornelissen, Annegien Broeks, Bernard M. Tijink, Lot A. Devriese, Remco de Bree, Christian U. Blank, Ton N. Schumacher, Daniela S. Thommen, John B.A.G. Haanen & Charlotte L. Zuur (2025) - Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial - Nature Medicine - doi: 10.1038/s41591-025-03943-w - [link]
- R. M.T. ten Ham, M. W. Rohaan, M. Egeler, R. Menezes, T. Holz Borch, R. Kessels, I. Jedema, B. Nuijen, C. M. Nijenhuis, L. V. van de Poll-Franse, M. H. Geukes Foppen, M. Lindenberg, I. Mansfield Noringriis, T. J. Monberg, M. Donia, W. van Harten, I. M. Svane, J. B.A.G. Haanen & V. P. Retèl (2025) - Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial - Annals of Oncology, 36 (10), 1154-1165 - doi: 10.1016/j.annonc.2025.06.005 - [link]
- Julie M. Vancoppenolle, Silvie H.M. Janssen, Nora Franzen, Winette T.A. van der Graaf, Valesca Retel, Olga Husson & Wim van Harten (2025) - Socioeconomic impact among and socioeconomic support services for adolescents and young adults with cancer: A European perspective - International Journal of Cancer, 157 (7), 1433-1445 - doi: 10.1002/ijc.35488 - [link]
- J. Vancoppenolle, N. Franzen, L. Azarang, T. Juslin, M. Krini, T. Lubbers, J. Mattson, D. Mayeur, R. Menezes, J. Schmitt, F. Scotte, O. Seoane López, T. Skaali, J. Ubels, M. Schlander, V. Retel, W. H. van Harten & (2025) - Financial toxicity and socioeconomic impact of cancer in Europe - ESMO Open, 10 (6) - doi: 10.1016/j.esmoop.2025.105293 - [link]
- Fábio Cardoso Borges, Winette T.A. van der Graaf, Robbe Saesen, Stefan Aebi, Ana E. Amariutei, Justin Bekelman, Thierry Gorlia, Frank Hulstaert, Isabelle Huys, Paul Kluetz, Michael J. Morris, Vijay Patil, Sheila A. Prindiville, Richard L. Schilsky, Andrew Thomson, Shaun Treweek, Michael Weller, Mira Zuidgeest, Valesca Retel & Denis Lacombe (2025) - Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer - The Lancet Oncology, 26 (5), e253-e263 - doi: 10.1016/S1470-2045(24)00756-3 - [link]
- Jinjing Fu, Nora Franzen, Eline Aas, J. C. Koen van der Mijn, Pim J. van Leeuwen & Valesca P. Retel (2025) - Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer - Value in Health, 28 (5), 720-729 - doi: 10.1016/j.jval.2025.02.004 - [link]
- Astrid Kramer, Lucas F. van Schaik, Daan van den Broek, , Gerrit A. Meijer, Iñaki Gutierrez Ibarluzea, Lorea Galnares Cordero, Remond J.A. Fijneman, Marjolijn J.L. Ligtenberg, Ed Schuuring, Wim H. van Harten, Veerle M.H. Coupé & Valesca P. Retèl (2025) - Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology - PharmacoEconomics, 43 (5), 483-497 - doi: 10.1007/s40273-025-01470-7 - [link]
- M. D. Egeler, E. Boomstra, M. W. Rohaan, N. M.J. Van den Heuvel, I. Fraterman, M. Delfos, L. V. van de Poll-Franse, T. H. Borch, I. M. Svane, J. B.A.G. Haanen, V. P. Retèl & A. H. Boekhout (2025) - “One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care - Journal of Cancer Survivorship, 19 (1), 109-120 - doi: 10.1007/s11764-023-01452-8 - [link]
- Zakile A. Mfumbilwa, Janneke A. Wilschut, Harry J.M. Groen, Valesca P. Retèl, Bram Ramaekers, Manuela Joore & Veerle M.H. Coupé (2025) - Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors - Clinical Drug Investigation, 45 (8), 583-598 - doi: 10.1007/s40261-025-01456-5 - [link]
- Danalyn Byng, Michael Schaapveld, Esther H. Lips, Frederieke H. van Duijnhoven, Jelle Wesseling, Wim H. van Harten & Valesca P. Retèl (2024) - An early economic evaluation of active surveillance for low-risk ductal carcinoma <i>in situ</i> - Future Oncology, 20 (40), 3451-3462 - doi: 10.1080/14796694.2024.2421152 - [link]
Health Economics Organisation European Cancer Inst
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- BRUSSEL
- Description
- Coordinator werkgroep
KWF
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- ROTTERDAM
- Description
- Lid beoordelingscommissie
NKI-AVL Amsterdam
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- AMSTERDAM
- Description
- Hoofd afdeling Health Technology Assessment
ZonMW
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- DEN HAAG
- Description
- Lid beoordelingscommissie
Master Thesis HE
- Year Level
- master, master
- Year
- 2025
- Course Code
- GW4592M
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2025
- Course Code
- GW4555M
